Literature DB >> 26728613

National trends and in hospital outcomes for total hip arthroplasty in avascular necrosis in the United States.

William Mayers1, Brian Schwartz2, Aaron Schwartz1, Vincent Moretti1, Wayne Goldstein1,3, Ritesh Shah1,3.   

Abstract

PURPOSE: While a majority of total hip arthroplasty (THA) is performed for osteoarthritis (OA), a significant portion is performed in the setting of avascular necrosis (AVN). The purpose of this study is to evaluate recent trends, patient demographics, and in hospital outcomes for primary THA in the setting of AVN in the United States.
METHODS: The National Hospital Discharge Survey database was searched for patients admitted to US hospitals after a primary THA for the years 2001-2010. Patients were then separated into two groups by ICD-9 diagnosis codes for OA and AVN.
RESULTS: The rates of THA for AVN (r = 0.65) and THA for OA (r = 0.82) both demonstrated a positive correlation with time. The mean patient age of the AVN group was significantly lower (56.9 vs 65.9 years, p < 0.01). Men accounted for 51.9 % of the AVN group and 43.0 % of the OA group (p < 0.01). The AVN group had a significantly higher percentage of African Americans (11.2 % vs 5.4 %, p < 0.01) when compared to the OA group. The AVN group had a higher rate of myocardial infarction (0.3 % vs 0.07 %, p = 0.0163) and a higher average number of medical co-morbidities (5.16 vs 4.77, p < 0.01).
CONCLUSIONS: Patients undergoing THA for AVN were more likely to be younger, male, African American, have more medical co-morbidities, and more likely to have a myocardial infarction than those with OA. While the number of primary THAs performed for AVN in the United States has increased over the past ten years, the rate of primary THA for OA increased at a much more rapid rate.

Entities:  

Keywords:  Avascular necrosis; Complications; Demographics; Osteoarthritis; Outcomes; Total hip arthroplasty

Mesh:

Year:  2016        PMID: 26728613     DOI: 10.1007/s00264-015-3089-8

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  23 in total

1.  Patient vs provider characteristics impacting hospital lengths of stay after total knee or hip arthroplasty.

Authors:  Joseph F Styron; Siran M Koroukian; Alison K Klika; Wael K Barsoum
Journal:  J Arthroplasty       Date:  2011-01-28       Impact factor: 4.757

Review 2.  Incidence and risk factors for deep surgical site infection after primary total hip arthroplasty: a systematic review.

Authors:  Donna M Urquhart; Fahad S Hanna; Sharon L Brennan; Anita E Wluka; Karin Leder; Peter A Cameron; Stephen E Graves; Flavia M Cicuttini
Journal:  J Arthroplasty       Date:  2009-10-30       Impact factor: 4.757

3.  The number of people with sickle-cell disease in the United States: national and state estimates.

Authors:  David C Brousseau; Julie A Panepinto; Mark Nimmer; Raymond G Hoffmann
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

4.  Results and complications of total hip arthroplasties in patients with sickle-cell hemoglobinopathies. Role of cementless components.

Authors:  J M Hickman; P F Lachiewicz
Journal:  J Arthroplasty       Date:  1997-06       Impact factor: 4.757

5.  Use of oral corticosteroids and the risk of acute myocardial infarction.

Authors:  Cristina Varas-Lorenzo; Luis Alberto Garcia Rodriguez; Andrew Maguire; Jordi Castellsague; Susana Perez-Gutthann
Journal:  Atherosclerosis       Date:  2006-06-19       Impact factor: 5.162

6.  Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement.

Authors:  Charlotte B Phillips; Jane A Barrett; Elena Losina; Nizar N Mahomed; Elizabeth A Lingard; Edward Guadagnoli; John A Baron; William H Harris; Robert Poss; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2003-01       Impact factor: 5.284

7.  Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head.

Authors:  Wakaba Fukushima; Mikihiro Fujioka; Toshikazu Kubo; Akiko Tamakoshi; Masaki Nagai; Yoshio Hirota
Journal:  Clin Orthop Relat Res       Date:  2010-03-12       Impact factor: 4.176

Review 8.  Acute myocardial infarction in sickle cell disease: a systematic review.

Authors:  Rajmony Pannu; Jun Zhang; Richard Andraws; Annemarie Armani; Praful Patel; Peter Mancusi-Ungaro
Journal:  Crit Pathw Cardiol       Date:  2008-06

9.  Total THA in adult osteonecrosis related to sickle cell disease.

Authors:  Philippe Hernigou; Sebastien Zilber; Paolo Filippini; Gilles Mathieu; Alexandre Poignard; Frederic Galacteros
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

10.  Treatment of femoral head osteonecrosis in the United States: 16-year analysis of the Nationwide Inpatient Sample.

Authors:  Aaron J Johnson; Michael A Mont; Audrey K Tsao; Lynne C Jones
Journal:  Clin Orthop Relat Res       Date:  2014-02       Impact factor: 4.176

View more
  3 in total

1.  Relative frequency of primary total hip arthroplasty for avascular necrosis in the United States as compared to a regional center: A data review.

Authors:  Sagie Haziza; Ramakanth R Yakkanti; Nathan A Wasserman; Michele R D'Apuzzo; Victor H Hernandez
Journal:  J Orthop       Date:  2022-09-27

2.  Bone-strengthening pill (BSP) promotes bone cell and chondrocyte repair, and the clinical and experimental study of BSP in the treatment of osteonecrosis of the femoral head.

Authors:  Zheng Li; Lulin Wang; Jin Wei; Liguo Zhu; Xisheng Weng; Jin Jin; Hong Xiao; Jun Zhang; Heming Wang; Guantong Shi; Lingpeng Pei; Fangde Zou; Wanqiang Zhang; Tianzun Tao; Xin Dong
Journal:  Oncotarget       Date:  2017-09-23

3.  Osteonecrosis of the Femoral Head.

Authors:  Gary George; Joseph M Lane
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.